LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
Cornelis M. van Tilburg(German Cancer Research Center), Olaf Witt(German Cancer Research Center), Katrin Scheinemann(University of Lucerne), Shivaram Avula(University of Liverpool), Pablo Hernáiz Driever(Charité - Universitätsmedizin Berlin), Peter Manley(Boston Children's Hospital), Till Milde(German Cancer Research Center), David Capper(German Cancer Research Center), Ofelia Cruz(Hospital Sant Joan de Déu Barcelona), Amedeo A. Azizi(Medical University of Vienna), Lindsay Kilburn(Children's National), David S. Ziegler(Cancer Institute of New South Wales), Felix Sahm(German Cancer Research Center), Astrid Sehested(Copenhagen University Hospital), Li‐Pen Tsao(NGM Biopharmaceuticals (United States)), Sébastien Perreault(Centre Hospitalier Universitaire Sainte-Justine), David Jones(German Cancer Research Center), Enrico Opocher(University of Padua), Michal Zápotocký(Charles University), René Schmidt(University of Münster), Jiaheng Qiu(University of California, Los Angeles), Arend Koch(Charité - Universitätsmedizin Berlin), Samuel C. Blackman, Ruth Witt(German Cancer Research Center), Antoinette Y. N. Schouten‐van Meeteren(Radboud University Nijmegen), Darren Hargrave(Great Ormond Street Hospital)
Cited by 66
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma
|Cancer Cell|2017|1.3k
The whole-genome landscape of medulloblastoma subtypes
|Nature|2017|1.2k